Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. - Wikidata - wikimedia - TriplyDB

Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.

Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.

http://www.wikidata.org/entity/Q43042142

about

The CCR5- 32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source Host Genetic Factors and Antiviral Immune Responses to Hepatitis C Virus Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection CCR5 haplotypes influence HCV serostatus in Caucasian intravenous drug users Interference with oligomerization and glycosaminoglycan binding of the chemokine CCL5 improves experimental liver injury Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment.Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation.CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.Effects of the Chemokine Receptor 5 (CCR5)-Delta32 Mutation on Hepatitis C Virus-Specific Immune Responses and Liver Tissue Pathology in HCV Infected Patients.Chemokines in the immunopathogenesis of hepatitis C infection The association of toll-like receptor 4 polymorphism with hepatitis C virus infection in Saudi Arabian patients.CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population.Clinical significance of the CCR5delta32 allele in hepatitis C CCR5 receptor: biologic and genetic implications in age-related diseases.Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearance Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells.Dysfunction of Immune Systems and Host Genetic Factors in Hepatitis C Virus Infection with Persistent Normal ALT.The history of the "natural history" of hepatitis C (1968-2009).Fibrosis progression in chronic hepatitis C virus infection.Host genetic determinants in hepatitis C virus infection.Predictive factors associated with hepatitis C antiviral therapy response.Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection -- a prospective cross-sectional study The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility.The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis.Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy.CCR1 and CCR5 promote hepatic fibrosis in mice A Study of CC-Chemokine Receptor 5 (CCR5) Polymorphism on the Outcome of HCV Therapy in Egyptian Patients.CCL5: a double-edged sword in host defense against the hepatitis C virus.Combinatorial use of single nucleotide polymorphisms to help predict liver fibrosis in patients with hepatitis C infections.Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.Stem cell-based therapies for HIV/AIDS.Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice.Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection.Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.Association of TIMP-1 and TIMP-2 gene polymorphisms with progression of liver fibrosis in patients with type C chronic liver disease.Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C.Role of CCR5Δ32 mutation in protecting patients with Schistosoma mansoni infection against hepatitis C viral infection or progression.

P2860

Q27477986-D7EBFAAE-B864-4821-B45D-D253EC2210BE Q27487445-53B0F1DC-90F7-46E7-98DD-7CAE8833400C Q27490393-7D1FE66D-7C76-4ADE-89AE-D4FCA4D9D8DB Q28534869-8E80AE5B-8DBF-4E62-93C2-502C839FCE71 Q28730116-AD74B623-72D3-4064-852D-D0C594D16917 Q33350754-BF432B11-48BA-4379-80CF-F856D46E5A29 Q33747313-B2B63EF6-762E-469D-AB54-A26669F53070 Q33867870-1A4126A6-D25D-4666-ADB0-827EBD1AA4AD Q33912466-EA18226A-98A7-4DD3-A6C6-815D1EE3ED05 Q34056271-278E8361-B45C-444D-93CF-EA4FD6F75C66 Q34081261-26099902-40A9-4A71-AD49-F9CD25D7BDD6 Q34098888-0DD43FE1-259D-41E1-BA95-ADE1D9D35031 Q34142349-6B13C767-6B5B-458F-B5D6-12496F02F489 Q34622935-53338022-F5D4-4671-A577-70A84539ABCE Q34914406-8AE5417E-3693-4A4A-8EEE-D43954392EC6 Q35009476-0ADA20E4-AB18-473B-A632-3B7C58ADE557 Q35046099-8845A73B-0F2B-48E2-93FE-2991B81EBDBB Q35094287-8018EFDD-CC2E-43B4-9C69-88A9FB6EF1B2 Q35216592-F3B6436A-744A-4BAB-B3B6-177B18E96DA9 Q35666213-4E1C4311-D542-4CB6-B3D3-BF325FA3E75E Q35753723-50463940-4EB3-4EE7-B8AA-01432A1E837B Q35790397-96AB3BF5-A83C-4D3C-8706-1A963A238FFA Q36503328-82668706-9617-43A0-86D6-5590875725AB Q36937324-9CD60E1A-5D26-4AFC-B73A-CC06F0248585 Q36944050-9C857048-259F-402C-AF70-CAD52D216B78 Q37196855-554B8102-E541-49AA-8B60-790B6EB1240D Q37225844-5DBD5BFF-C548-4D53-ADB9-7AB44C6B4FBA Q37241370-8C05752D-55AD-4ECC-95B9-B17044C1DF86 Q37424353-EA00597F-93D6-4FD5-8613-3EC39DFADAC9 Q37952808-489B5DAD-DFAC-402C-87DF-82B0D3188150 Q38088855-349B1AAD-C82B-49E3-96BA-126C9DF4B5A9 Q38157936-5CC01A75-78FD-4685-A841-1038204A2A71 Q38827119-60491AD8-E5AA-4B2F-94BD-0CE0A46B696A Q39639458-E97A1D77-FF16-48B9-8849-15E283289E43 Q42984759-176957F4-184C-4534-BBA4-4DCCEC00E31E Q42988911-E0887632-9C47-44FC-BE4F-0EF21C91BD2C Q43023517-32980E6F-EAC9-405A-BB0A-368E6C01BFFC Q43742587-4B984778-B522-4E7E-97FF-DBBE49560426 Q44246682-89862B9E-6D6D-41E7-B898-59ABC9C66EBD Q44394482-066630A0-09B9-4854-A592-01A326400CD8

P2860

Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.

http://www.wikidata.org/entity/Q43042142

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Associations of chemokine syst ...... ponses of chronic hepatitis C.

@en

Associations of chemokine syst ...... ponses of chronic hepatitis C.

@nl

type

label

Associations of chemokine syst ...... ponses of chronic hepatitis C.

@en

Associations of chemokine syst ...... ponses of chronic hepatitis C.

@nl

prefLabel

Associations of chemokine syst ...... ponses of chronic hepatitis C.

@en

Associations of chemokine syst ...... ponses of chronic hepatitis C.

@nl

P1433

Q43042142-81ED6E65-274E-4089-AD98-1926A98FB244

P1476

Q43042142-AB3B8C97-0DA7-4CEA-AC90-DA6F112E31E2

P2093

Q43042142-080D0997-D4C4-4F0F-9770-591565C33B4D

Q43042142-11F1C0BF-82A3-41CB-A52E-D7F677469DCB

Q43042142-205C63F1-C8EF-47CE-AC15-7125FCC30245

Q43042142-21D442DD-F1BC-4574-AF8E-3C69BB5D3362

Q43042142-5EF66287-DC82-485B-B031-28A99A6CAD12

Q43042142-756671A7-E1A8-4C9B-8D06-96DA2B374D26

Q43042142-7EB3EA9A-5CE6-4F8C-9CFF-BEBC5935BCE1

Q43042142-8AABB15D-C1C9-42A5-9D1E-4695F3EE855C

Q43042142-951019F2-241F-4EFA-A98D-E4F1EBB825A5

Q43042142-DA747D4F-3BE9-4533-8CF1-2FC8920BF728

P304

Q43042142-F0898D80-CA50-4CBA-9EF7-DA3D17AE80BF

P31

Q43042142-DB7E0B74-EF82-45F6-A83E-9A1D46F48FAB

P356

Q43042142-406E4034-3363-47CD-8078-71C1C80ED3E7

P407

Q43042142-5D6D87CF-150C-47B4-9265-B124E991DA96

P433

Q43042142-A6589C3E-DD46-491B-BE77-63C4985E7968

P478

Q43042142-4291A68A-6060-43D5-BA53-D9B80A1B8301

P50

Q43042142-5FFDD842-3A63-478C-B20A-E8AD245A74D6

Q43042142-98EC1609-3937-4EFA-9F6F-107AC50270F4

Q43042142-E280AE2E-1C8B-4646-84EB-64CEC58A9BC9

P577

Q43042142-4B738458-B6A1-4AD6-BD31-A34F87FF4909

P5875

Q43042142-1EB791F2-3317-4A2A-8FFD-8FC0562E6D71

P698

Q43042142-5F8F6BAA-A175-410B-8EE6-D5FA92DBD1A1

P356

GAST.2003.50061

P1433

Gastroenterology

P1476

Associations of chemokine syst ...... ponses of chronic hepatitis C.

@en

P2093

Alejandro Soza

http://www.w3.org/2001/XMLSchema#string

Carlos M Gonzalez

http://www.w3.org/2001/XMLSchema#string

Deloris E Koziol

http://www.w3.org/2001/XMLSchema#string

Harvey J Alter

http://www.w3.org/2001/XMLSchema#string

Jay H Hoofnagle

http://www.w3.org/2001/XMLSchema#string

Kittichai Promrat

http://www.w3.org/2001/XMLSchema#string

Marc Ghany

http://www.w3.org/2001/XMLSchema#string

Matthew Lessie

http://www.w3.org/2001/XMLSchema#string

Maya Merrell

http://www.w3.org/2001/XMLSchema#string

T Jake Liang

http://www.w3.org/2001/XMLSchema#string

P304

352-360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/GAST.2003.50061

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

David H. McDermott

David E. Kleiner

Philip M Murphy

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10926632

http://www.w3.org/2001/XMLSchema#string

P698

12557141

http://www.w3.org/2001/XMLSchema#string